Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
22
ALNY Quote, Financials, Valuation and Earnings
Last price:
$313.78
Seasonality move
:
-4.14%
Day range:
$298.00 - $315.51
52-week range:
$205.87 - $495.55
Dividend yield:
0%
P/E ratio:
1,282.66x
P/S ratio:
12.66x
P/B ratio:
174.24x
Volume:
2.9M
Avg. volume:
1.6M
1-year change:
15.99%
Market cap:
$40.8B
Revenue:
$2.2B
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
ABBV
AbbVie, Inc.
|
$16.4B | $2.65 | 10.4% | 319.23% | $245.33 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.62 | -4.11% | 84.68% | $205.52 |
|
INSM
Insmed, Inc.
|
$264M | -$1.16 | 192.54% | -43.17% | $215.15 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.61% | 137.25% | $1,201.63 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.25% | 39.47% | $28.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$308.48 | $479.79 | $40.8B | 1,282.66x | $0.00 | 0% | 12.66x |
|
ABBV
AbbVie, Inc.
|
$227.50 | $245.33 | $402.1B | 96.11x | $1.73 | 2.92% | 6.59x |
|
BIIB
Biogen, Inc.
|
$195.50 | $205.52 | $28.7B | 22.20x | $0.00 | 0% | 3.01x |
|
INSM
Insmed, Inc.
|
$146.17 | $215.15 | $31.2B | -- | $0.00 | 0% | 62.20x |
|
LLY
Eli Lilly & Co.
|
$1,038.27 | $1,201.63 | $929.3B | 45.23x | $1.73 | 0.58% | 14.33x |
|
PFE
Pfizer Inc.
|
$27.47 | $28.63 | $156.2B | 20.27x | $0.43 | 6.26% | 2.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
ABBV
AbbVie, Inc.
|
104% | -0.239 | -- | 0.47x |
|
BIIB
Biogen, Inc.
|
26.72% | 0.777 | 25.77% | 1.70x |
|
INSM
Insmed, Inc.
|
44.07% | 2.488 | 2.43% | 4.18x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.536 | -- | 0.65x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
ABBV
AbbVie, Inc.
|
$14B | $5.8B | 6.03% | 144.3% | 34.96% | $6.6B |
|
BIIB
Biogen, Inc.
|
$1.5B | $361.2M | 5.34% | 7.36% | 16.56% | $401.7M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
LLY
Eli Lilly & Co.
|
$16B | $9B | 36.39% | 106.26% | 46.58% | $6B |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
Alnylam Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ALNY or ABBV?
AbbVie, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 10.92%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B ABBVAbbVie, Inc.84.02% $1.02 $66.1B -
What do Analysts Say About ALNY or ABBV?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $479.79, signalling upside risk potential of 55.53%. On the other hand AbbVie, Inc. has an analysts' consensus of $245.33 which suggests that it could grow by 7.84%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than AbbVie, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.13 8 0 ABBVAbbVie, Inc.13 9 0 -
Is ALNY or ABBV More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.025% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.985%.
-
Which is a Better Dividend Stock ALNY or ABBV?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.92% to investors and pays a quarterly dividend of $1.73 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 279% of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or ABBV?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than AbbVie, Inc. quarterly revenues of $16.6B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than AbbVie, Inc.'s net income of $1.8B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,282.66x while AbbVie, Inc.'s PE ratio is 96.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 12.66x versus 6.59x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.12.66x 1,282.66x $1.2B $251.1M ABBVAbbVie, Inc.6.59x 96.11x $16.6B $1.8B
-
Which has Higher Returns ALNY or BIIB?
Biogen, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -2.24%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Biogen, Inc.'s return on equity of 7.36%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B BIIBBiogen, Inc.68.1% -$0.33 $24.9B -
What do Analysts Say About ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $479.79, signalling upside risk potential of 55.53%. On the other hand Biogen, Inc. has an analysts' consensus of $205.52 which suggests that it could grow by 5.12%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.13 8 0 BIIBBiogen, Inc.14 18 1 -
Is ALNY or BIIB More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.025% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.
-
Which is a Better Dividend Stock ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or BIIB?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Biogen, Inc.'s net income of -$48.9M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,282.66x while Biogen, Inc.'s PE ratio is 22.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 12.66x versus 3.01x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.12.66x 1,282.66x $1.2B $251.1M BIIBBiogen, Inc.3.01x 22.20x $2.2B -$48.9M
-
Which has Higher Returns ALNY or INSM?
Insmed, Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -259.95%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About ALNY or INSM?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $479.79, signalling upside risk potential of 55.53%. On the other hand Insmed, Inc. has an analysts' consensus of $215.15 which suggests that it could grow by 47.19%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.13 8 0 INSMInsmed, Inc.18 1 0 -
Is ALNY or INSM More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.025% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock ALNY or INSM?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or INSM?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,282.66x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 12.66x versus 62.20x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.12.66x 1,282.66x $1.2B $251.1M INSMInsmed, Inc.62.20x -- $142.3M -$370M
-
Which has Higher Returns ALNY or LLY?
Eli Lilly & Co. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of 34.4%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B LLYEli Lilly & Co.83.16% $7.39 $66.4B -
What do Analysts Say About ALNY or LLY?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $479.79, signalling upside risk potential of 55.53%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.73%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.13 8 0 LLYEli Lilly & Co.18 6 0 -
Is ALNY or LLY More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.025% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock ALNY or LLY?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.73 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ALNY or LLY?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,282.66x while Eli Lilly & Co.'s PE ratio is 45.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 12.66x versus 14.33x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.12.66x 1,282.66x $1.2B $251.1M LLYEli Lilly & Co.14.33x 45.23x $19.3B $6.6B
-
Which has Higher Returns ALNY or PFE?
Pfizer Inc. has a net margin of 20.1% compared to Alnylam Pharmaceuticals, Inc.'s net margin of -9.34%. Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About ALNY or PFE?
Alnylam Pharmaceuticals, Inc. has a consensus price target of $479.79, signalling upside risk potential of 55.53%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 4.22%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALNYAlnylam Pharmaceuticals, Inc.13 8 0 PFEPfizer Inc.7 15 1 -
Is ALNY or PFE More Risky?
Alnylam Pharmaceuticals, Inc. has a beta of 0.350, which suggesting that the stock is 65.025% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock ALNY or PFE?
Alnylam Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.26% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios ALNY or PFE?
Alnylam Pharmaceuticals, Inc. quarterly revenues are $1.2B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Alnylam Pharmaceuticals, Inc.'s net income of $251.1M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Alnylam Pharmaceuticals, Inc.'s price-to-earnings ratio is 1,282.66x while Pfizer Inc.'s PE ratio is 20.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals, Inc. is 12.66x versus 2.50x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALNYAlnylam Pharmaceuticals, Inc.12.66x 1,282.66x $1.2B $251.1M PFEPfizer Inc.2.50x 20.27x $17.6B -$1.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 15.9% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 0.31% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 2.47% over the past day.
